• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thoracic cancer. >Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra‐central non‐small cell lung cancer
【24h】

Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra‐central non‐small cell lung cancer

机译：高级中非小细胞肺癌立体定向体放射治疗的结果和毒性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Previous studies have documented a high incidence of toxicity in patients with ultra-central non-small cell lung cancer (UC-NSCLC) treated with stereotactic body radiation therapy (SBRT). However, these studies mainly focused on early stage patients and included small sample populations. We reviewed the outcomes and toxicity of SBRT in patients with advanced stage UC-NSCLC treated at our institution. Fifty-one consecutive patients with advanced UC-NSCLC treated with SBRT using a regular regimen of 35?Gy administered in five fractions between December 2014 and August 2017 were reviewed. UC was defined as tumors abutting or overlapping the trachea or the proximal bronchial tree. We included locally advanced patients who were unfit or unwilling to receive conventional chemoradiotherapy and patients with metastatic or postoperative recurrent disease. Clinical outcomes, dosimetric parameters, and SBRT toxicity were analyzed. The median age was 63?years (range: 35-82), and the median tumor diameter was 6.8 cm (range: 2.1-12.4). The overall median follow-up duration was 17?months (25.5 months for surviving patients). The median local control was 17?months for stage III patients and 11?months for stage IV or recurrent patients. Grade 3 or higher toxicity was observed in 9.8% of patients: G3 radiation pneumonitis (5.9%) and possible treatment-related death (3.9%). SBRT with a moderate dose in 4-6 fractions is effective and tolerable for patients with advanced stage UC-NSCLC. However, caution should be taken considering possible treatment-related death. Further studies are warranted. ? 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译：以前的研究已经记录了用立体定向体放射治疗（SBRT）处理的超中央非小细胞肺癌（UC-NSCLC）患者毒性的高发病率。然而，这些研究主要集中在早期患者上，包括小样本群体。我们在我们机构治疗的高级UC-NSCLC患者中审查了SBRT的结果和毒性。综述了在2014年12月至2017年12月间在五分之一的常规方案治疗的患有SBRT治疗的先进UC-NSCLC患者。 UC被定义为脱落或重叠气管或近端支气管树的肿瘤。我们包括局部先进的患者，该患者不合适或不愿接受常规的化学疗法和转移性或术后复发性疾病的患者。分析了临床结果，剂量测定参数和SBRT毒性。中位年龄为63岁（范围：35-82），中位数肿瘤直径为6.8厘米（范围：2.1-12.4）。整体中位后续持续时间为17？月份（存活患者25.5个月）。中位数局部对照是第III期患者的17个月，阶段IV患者11个月，阶段IV或复发患者。在9.8％的患者中观察到3级或更高的毒性：G3辐射肺炎（5.9％）和可能的治疗相关死亡（3.9％）。在4-6个级分中具有中等剂量的SBRT对于高级UC-NSCLC的患者有效和可耐受。但是，考虑到可能的治疗相关死亡，应注意谨慎。进一步的研究是有必要的。 ？ 2019年的作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号